Posted on 04/12/2009 in Pharmacy Supplier News Teva UK has introduced its first-ever biosimilar medicine to pharmacies.
TevaGrastim - a proprietary version of filgrastim - represents a major addition to Teva's hospital products portfolio and is indicated for a number of treatment areas.
A biosimilar is sometimes referred to as a biogeneric and is defined as a similar biological medicinal product.
TevaGrastim can be used to reduce chemotherapy-induced neutropenia and is available in 30 MIU pre-filled syringes and 48 MIU pre-filled syringes.
The product's packaging will also feature a needle guard to minimise the risk of accidental injuries among patients.
According to Teva UK, TevaGrastim is a competitively priced3 G-CSF treatment when comparing NHS list prices of filgrastim products.
Teva was established 70 years ago and is focused on several areas, such as generics, respiratory and hospital products.
Among these are Carboplatin, Cisplatin, Doxorubin, Etoposide and Calcium Folinate.
On an international scale, Teva has over 26,000 employees. Other news stories from 04/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
